` BLRX (BioLine RX Ltd) vs Tel Aviv 355 Comparison - Alpha Spread

BLRX
vs
Tel Aviv 355

Over the past 12 months, BLRX has underperformed Tel Aviv 355, delivering a return of -84% compared to the Tel Aviv 355's 46% growth.

Stocks Performance
BLRX vs Tel Aviv 355

Loading
BLRX
Tel Aviv 355
Add Stock
www.alphaspread.com

Performance Gap
BLRX vs Tel Aviv 355

Loading

Over the past 12 months, BLRX has underperformed Tel Aviv 355 by 130.35%.

BLRX
Tel Aviv 355
Difference
www.alphaspread.com

Performance By Year
BLRX vs Tel Aviv 355

Loading
BLRX
Tel Aviv 355
Add Stock

Competitors Performance
BioLine RX Ltd vs Peers

Tel Aviv 355
BLRX
ABBV
AMGN
GILD
VRTX
Add Stock

BioLine RX Ltd
Glance View

Market Cap
57.3m ILS
Industry
Biotechnology

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

BLRX Intrinsic Value
17.21 ILS
Undervaluation 85%
Intrinsic Value
Price
B
Back to Top